| 000 | 01630 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250516104712.0 | ||
| 264 | 0 | _c20130111 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a1558-4410 | ||
| 024 | 7 |
_a10.1016/j.ecl.2012.04.007 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDiab, Dima L | |
| 245 | 0 | 0 |
_aBisphosphonates in the treatment of osteoporosis. _h[electronic resource] |
| 260 |
_bEndocrinology and metabolism clinics of North America _cSep 2012 |
||
| 300 |
_a487-506 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnticarcinogenic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAtrial Fibrillation _xchemically induced |
| 650 | 0 | 4 |
_aBisphosphonate-Associated Osteonecrosis of the Jaw _xcomplications |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aDiphosphonates _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 |
_aEsophageal Neoplasms _xchemically induced |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFemoral Fractures _xchemically induced |
| 650 | 0 | 4 |
_aGastrointestinal Diseases _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMusculoskeletal Pain _xchemically induced |
| 650 | 0 | 4 |
_aOsteoporosis _xcomplications |
| 650 | 0 | 4 |
_aOsteoporosis, Postmenopausal _xcomplications |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aStroke _xprevention & control |
| 700 | 1 | _aWatts, Nelson B | |
| 773 | 0 |
_tEndocrinology and metabolism clinics of North America _gvol. 41 _gno. 3 _gp. 487-506 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ecl.2012.04.007 _zAvailable from publisher's website |
| 999 |
_c22011452 _d22011452 |
||